Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Fosun International Limited
  6. News
  7. Summary
    656   HK0656038673

FOSUN INTERNATIONAL LIMITED

(656)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Shares of China vaccine makers slump on U.S. waiver support

05/06/2021 | 02:57am EDT
FILE PHOTO: China's vaccine specialist CanSino Biologics Inc in Tianjin

SHANGHAI (Reuters) - Shares in Chinese vaccine makers slumped on Thursday after U.S. President Joe Biden's support for a proposed waiver of intellectual property rights on COVID-19 vaccines sent investors scrambling to reconsider high valuations.

The Shanghai shares of CanSino Biologics Inc, a single-dose COVID-19 vaccine maker, tumbled as much as 16.91%. The company's Hong Kong shares fell even further, at one point diving nearly 22%.

Shares of Shanghai Fosun Pharmaceutical Group fell by the 10% daily limit, as the CSI300 healthcare sub-index dropped more than 5%.

On Wednesday, Biden indicated his support for a waiver amid growing concern that big outbreaks in India could allow the rise of vaccine-resistant strains of the deadly virus, undermining a global recovery.

Any decision by the World Trade Organization on waivers for COVID-19 vaccines requires a consensus of all 164 members.

Worsening outbreaks have boosted demand for vaccine stocks in China's retail-driven equity market.

"The patent waiver will definitely have some impact on China's domestic COVID-19 vaccine makers, as it would increase the global vaccine supply," said Hu Yunlong, a Beijing-based fund manager.

"The fall in Chinese vaccine makers is also partly due to a technical correction following their recent sharp gains."

China's healthcare sub-index jumped nearly 11% last month, adding froth to the already-high valuations in the sector. Data from China Securities Index Co showed the price-to-earnings ratio for the healthcare sector at above 62, as of April 30, compared with around 21 for the Shanghai and Shenzhen stock exchanges overall.

"Chinese vaccine stocks had been spurred recently by news of worsening situations in other countries, such as India," said Wu Tianhao, an analyst at Western Securities.

While the patent waiver could hurt exports of Chinese vaccines, the overall impact on the sector would be limited.

"Domestic sales are still their main source of revenue," Wu said.

(Reporting by Luoyan Liu, Samuel Shen and Andrew Galbraith; Editing by Subhranshu Sahu)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
CANSINO BIOLOGICS INC. 4.88% 357 End-of-day quote.102.27%
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. 0.45% 179.7 End-of-day quote.21.49%
FOSUN INTERNATIONAL LIMITED 2.15% 11.4 End-of-day quote.-6.40%
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. 0.72% 62.7 End-of-day quote.16.13%
WESTERN SECURITIES CO., LTD. 0.73% 8.32 End-of-day quote.-17.95%
All news about FOSUN INTERNATIONAL LIMITED
06/11VIEWRAY  : Insider Sales at ViewRay (VRAY) are Significant
MT
06/10MARKET CHATTER : Juneyao Airlines, Trip.com Seen Bidding for HNA Assets
MT
06/10INSIDER TRENDS : Insider Adds to Selling Trend at ViewRay
MT
06/09SHANGHAI FOSUN PHARMACEUTICAL  : Fosun, CQ Pharma Enter Into Mutual Supply Agree..
MT
06/08FOSUN INTERNATIONAL LIMITED : Ex-dividend day for final dividend
FA
06/03Xiaomi-Backed Fund Joins $190 Million Funding Round For Self-Driving Startup ..
MT
05/25Fosun High Tech, Fosun International Buy Shares of Shanghai Fosun Pharma
MT
05/24SABOO SODIUM CHLORO  : Bags Purchase Order Worth $5 Million
MT
05/23MARKET CHATTER : Shanghai AJ Group, Juneyao Airlines Team Up to Bid for HNA's Ai..
MT
05/22China's Fosun says willing to provide BioNTech vaccines to Taiwan
RE
More news
Financials
Sales 2021 153 B 23 746 M 23 746 M
Net income 2021 13 191 M 2 044 M 2 044 M
Net Debt 2021 108 B 16 757 M 16 757 M
P/E ratio 2021 5,88x
Yield 2021 3,67%
Capitalization 79 396 M 12 304 M 12 305 M
EV / Sales 2021 1,22x
EV / Sales 2022 1,13x
Nbr of Employees 76 000
Free-Float 27,7%
Chart FOSUN INTERNATIONAL LIMITED
Duration : Period :
Fosun International Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FOSUN INTERNATIONAL LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Average target price 11,04 CNY
Last Close Price 9,48 CNY
Spread / Highest target 32,5%
Spread / Average Target 16,5%
Spread / Lowest Target 4,06%
EPS Revisions
Managers and Directors
NameTitle
Qi Yu Chen Co-Chief Executive Officer & Executive Director
Xiao Liang Xu Co-Chief Executive Officer & Executive Director
Ping Gong Chief Financial Officer & Executive Director
Hou Lin Zhang Co-Chief Financial Officer & Senior Vice President
Li Gang Zhang Co-CFO & GM-Financial Management
Sector and Competitors
1st jan.Capitalization (M$)
FOSUN INTERNATIONAL LIMITED-6.40%12 304
ALLIANZ SE8.27%106 150
CHUBB LIMITED1.36%70 156
MARSH & MCLENNAN COMPANIES, INC.16.96%68 301
ZURICH INSURANCE GROUP AG0.62%60 500
BAJAJ FINSERV LTD.34.73%25 749